Shopping Cart
Remove All
Your shopping cart is currently empty
Anrukinzumab (Synonyms: IMA-638)
Catalog No. T76906 Copy Product Info
🥰Excellent
Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Anrukinzumab
Copy Product Info🥰Excellent
Catalog No. T76906
Synonyms IMA-638
Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma.
Anrukinzumab
Cas No. 910649-32-0
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | - | In Stock | |
| 5 mg | $645 | - | In Stock | |
| 10 mg | $987 | - | In Stock | |
| 25 mg | $1,460 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.0% (SDS-PAGE); 98.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Anrukinzumab (IMA-638) is a humanized monoclonal antibody that specifically targets and neutralizes interleukin-13 (IL-13). Anrukinzumab has demonstrated significant anti-inflammatory effects in validated non-human primate models of disease, supporting its ongoing research for the treatment of ulcerative colitis (UC) and asthma. |
| In vivo | Methods: Anrukinzumab (10 mg/kg, intravenous injection, single dose) was used to treat adult male cynomolgus monkeys with lung inflammation to observe its therapeutic effect. Results: Anrukinzumab was able to reduce the total cell count, eosinophil count, and neutrophil count in bronchoalveolar lavage (BAL) fluid. [1] |
| Synonyms | IMA-638 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | IL-13 |
| Molecular Weight | 145.38 kDa |
| Cas No. | 910649-32-0 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
Preview
Related Tags: buy Anrukinzumab | purchase Anrukinzumab | Anrukinzumab cost | order Anrukinzumab | Anrukinzumab in vivo | Anrukinzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.